FournierJC, DeRubeisRJ, HollonSD, DimidjianS, AmsterdamJD, SheltonRC, FawcettJ. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA, 303:47–53. 2010.
2.
GibbonsRD, HurK, BrownH, DavisJM, MannJJ. Benefits from antidepressants: Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry, 69:572–579. 2012a.
3.
GibbonsRD, BrownH, HurK, DavisJM, MannJJ. Suicidal thoughts, behavior with antidepressant treatment: Reanalysis of the randomized placebo-controlled studies of fluoxetine, venlafaxine. Arch Gen Psychiatry, 69:580–587. 2012b.
4.
KirschJ, DeaconBJ, Huedo-MedinaTB, ScoboriaA, MooreTJ, JohnsonBT. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLOS, 5,2:e45. 2008.
5.
MarchJ, SilvaS, PetryckiS, CurryJ, WellsK, FairbankJ, BurnsB, DominoM, McNultyS, VitielloB, SevereJ. Treatment for Adolescents with Depression Study (TADS) Team: Fluoxetine, cognitive-behavior therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA, 292:807–820. 2004.
6.
MatthewSJ, CharneyDS. Publication bias and the efficacy of antidepressants. Am J Psychiatry, 166:140–145. 2009.
7.
TurnerEH, MatthewsAM, LinardatosE, TellRA, RosenthalR. Selective publication of antidepressant trials and its influence on apparent efficacy. NEJM, 358:252–260. 2008.
